Which Healthcare ETF Is the Better Buy: Simplify’s Active PINK or VanEck’s Pharma-Focused PPH?

VanEck Pharmaceutical ETF (PPH) is presented as the stronger choice for most long-term investors, with a 0.36% expense ratio, 1.9% trailing yield and longer track record, versus 0.51%, 0.8% and a 2021 launch for Simplify Health Care ETF (PINK). PINK returned 18.4% over the past year versus PPH’s 16.8%, but had higher beta (0.73 versus 0.45); the article highlights its active management and commitment to donate net profits to breast cancer research.

Analysis

The apparent choice is less “broad healthcare versus pharma” than a factor bet: PPH makes investors materially more dependent on a few large drugmakers, particularly LLY, while PINK spreads exposure across more varied healthcare business models, including HUM and ARQT. That distinction matters more than the 15-basis-point fee gap; over a year, the fee difference is unlikely to dominate outcomes, whereas one company-specific earnings or policy shock could.

PPH’s concentration makes it a cleaner vehicle for a continued large-cap pharma/GLP-1 thesis, but also leaves it exposed to valuation, competitive, and drug-pricing reversals in a small number of holdings. PINK’s active approach may diversify those drivers, but creates manager-selection risk and potentially greater sensitivity to biotech and insurer-specific news. Its reported higher trailing return is not evidence of persistent skill, particularly given its shorter history and higher reported beta. Neither fund’s past drawdown establishes how it would behave in a sector-specific selloff.

Near term, this comparison alone is not a catalyst. Over 1–3 months, monitor LLY/NVO results and guidance, drug-pricing or reimbursement developments, and PINK’s holdings and flows. Over 6–18 months, the key question is whether pharma growth broadens beyond the largest names or becomes more concentrated. The charitable claim also needs prospectus verification: the article alternates between donating “net profits” and donating the management fee. A donation is not automatically an investor return or fee waiver.

Key Decisions for Investors

• No standalone trade on this article. For a deliberate large-cap pharma/GLP-1 overweight, PPH is the more direct expression; size it for concentration risk rather than treating its lower fee or reported beta as protection.
• Avoid a mechanical PPH-versus-PINK pair without checking current holdings, overlap, spreads, and liquidity. Such a pair would partly trade pharma concentration against active exposure to other healthcare subsectors, not simply manager performance.
• Treat PINK’s trailing outperformance as unproven. Reassess only after reviewing holdings changes, benchmark-relative returns across a longer period, and whether flows or trading costs materially affect execution.
• Falsify the PPH-overweight thesis if LLY/NVO guidance weakens, competitive or reimbursement pressure broadens, or pharma earnings revisions turn down. For PINK, verify the donation and fee language in fund documents and monitor whether active positioning actually reduces exposure to the risks investors seek to avoid.